Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN 2 Study

Trial Profile

Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN 2 Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Carboplatin; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TRAIN-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Primary endpoint (Number of patients with pathological complete response) has not been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top